Cost, quality, and risk: Measuring and stopping the hidden costs of coronary artery bypass graft surgery

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 4, 2005, Pages

  Morgan, Timothy O ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Blood; Control, quality; Coronary artery bypass; Costs; Economics; Hospitals; Protocols; Risk management; Team; Toxicity

Indexed keywords

BLOOD STORAGE; BLOOD TRANSFUSION; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH HAZARD; HOSPITAL COST; MEDICAL STAFF; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY CONTROL; RISK MANAGEMENT; SOCIOECONOMICS;

EID: 24944542266     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050301     Document Type: Conference Paper

References (16)

1. Spiess BD, Royston D, Levy JH et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44(8):1143-8.
2. Bucerius J, Gummert JF, Borger MA et al. Stroke after cardiac surgery, a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg. 2003; 75(2):472-8.
3. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol. 1997; 34(3 Suppl 2):34-40.
4. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion. 2003; 43(5):668-76.
5. Green JA, Reynolds PS, Makhoul K et al. Potential financial savings of a bloodless cardiac surgery initiative. Anesth Analg. 2003; 96:17.
6. Green JA, Reynolds PS, Makhoul K et al. Evaluating the transfusion effects on outcome for patients undergoing primary coronary artery bypass grafting. Anesth Analg. 2003; 96:16.
7. Green JA, Spiess BD, Reynolds PS et al. Evaluation of a bloodless cardiac surgery protocol for patients undergoing primary coronary artery bypass grafting. Anesth Analg. 2003; 96:46.
8. Higgins R, DeAnda A, Kasirajan V et al. Challenging the transfusion trigger in cardiac surgery, impact on resource utilization, transfusion rates and outcomes. Circulation. 2002; 106(15):37.
9. Etchason J, Petz L, Keeler E et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995; 332 (11):719-24.
10. Sonnenberg FA, Gregory P, Yomtovian R et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion. 1999; 39(8):808-17.
11. Trasylol® (aprotinin injection) package insert. West Haven, CT: Bayer Pharmaceuticals Corporation; 2003 Dec.
12. Smith PK, Datta SK, Muhlbaier LH et al. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Ann Thorac Surg. 2004; 77(2):635-42.
13. Lemmer JH, Jr., Dilling EW, Morton JR et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg. 1996; 62(6):1659-67.
14. Levy JH, Pifarre R, Schaff HV et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995; 92(8):2236-44.
15. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004; 128(3):442-8.
16. Ford P, Mastoris J, Badani K et al. Profitability of medical procedures without the use of transfusion support. Blood. 2004; 104(11):5316.